



**Senate Bill No. 191**

**Public Act No. 26-108**

***AN ACT CONCERNING THE PSYCHEDELIC-ASSISTED THERAPY PILOT PROGRAM.***

Be it enacted by the Senate and House of Representatives in General Assembly convened:

Section 1. Section 17a-484g of the general statutes is repealed and the following is substituted in lieu thereof (*Effective July 1, 2026*):

(a) As used in this section:

(1) "MDMA" means the synthetic psychoactive drug, 3,4-methylenedioxymethamphetamine, commonly known as ecstasy or molly, that acts as a serotonin receptor agonist and reuptake inhibitor of serotonin and dopamine.

(2) "Psilocybin" means a serotonin receptor agonist that occurs naturally in some mushroom species.

(3) "Qualified patient" means an individual who is eighteen years of age or older and meets clinical eligibility criteria established by the institutional review board of the medical school selected to administer the pilot program under subsection (b) of this section, including, but not limited to, a resident of the state who is (A) a veteran, (B) a retired first responder, or (C) a direct care health care worker.

**Senate Bill No. 191**

(b) [Not later than January 1, 2023, the] The Department of Mental Health and Addiction Services shall establish, within available appropriations, a psychedelic-assisted therapy pilot program, to be administered by a medical school in the state. Such pilot program shall provide qualified patients with MDMA-assisted or psilocybin-assisted therapy as part of a research program approved by the federal Food and Drug Administration pursuant to 21 CFR 312, as amended from time to time. [The department shall cease to operate the pilot program when MDMA and psilocybin have been approved to have a medical use by the Drug Enforcement Administration, or any successor agency.]